Hypertension Labeling Should Say Classes Are All Effective, But Unequally So

Antihypertensive drug class labeling for cardiovascular outcomes should specify that some classes of agents are more effective at reducing such events than others, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said